TYME Tyme Technologies Inc.

1.33
-0.13  -9%
Previous Close 1.46
Open 1.44
Price To Book 12.09
Market Cap 148,894,746
Shares 111,950,937
Volume 608,457
Short Ratio
Av. Daily Volume 452,631
Stock charts supplied by TradingView

NewsSee all news

  1. LineaRx's iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial

    LineaRx Platform Used in Phase II trial in recurrent prostate cancer demonstrates the number of circulating tumor cells correlates more directly with disease status LineaRx, Inc., the majority-owned subsidiary of

  2. TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer

    Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising prostate-specific antigen (PSA):  More than 450,000 of

  3. TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer

    TYME launched its multicenter randomized controlled pivotal stage of TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer based on these clinical outcomesSM-88 is an oral, investigational

  4. TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer

    Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers with demonstrated responses in 15 different cancer types across four separate studiesData presented at ESMO GI 2019 from

  5. Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

    NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 presentation at ESMO September 29, 2019.
SM-88
Pancreatic cancer
Pivotal stage initiation announced September 25, 2019.
SM-88
Prostate cancer
Phase 1/2 initiation announced May 23, 2019.
SM-88
Ewing’s sarcoma

Latest News

  1. LineaRx's iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial

    LineaRx Platform Used in Phase II trial in recurrent prostate cancer demonstrates the number of circulating tumor cells correlates more directly with disease status LineaRx, Inc., the majority-owned subsidiary of

  2. TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer

    Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising prostate-specific antigen (PSA):  More than 450,000 of

  3. TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer

    TYME launched its multicenter randomized controlled pivotal stage of TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer based on these clinical outcomesSM-88 is an oral, investigational

  4. TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer

    Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers with demonstrated responses in 15 different cancer types across four separate studiesData presented at ESMO GI 2019 from

  5. Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

    NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the

  6. TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019

    TYME-88-PANC Phase II study showed patients being treated with SM-88, who achieved at least an 80% reduction in circulating tumor cell burden, demonstrated a 60% decrease in risk of deathSM-88 is an oral, investigational

  7. Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the